Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma
Open Access
- 24 March 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 17 (8), 934-942
- https://doi.org/10.1002/lt.22307
Abstract
Mixed hepatocellular cholangiocarcinoma (HCC-CC) and intrahepatic cholangiocarcinoma (I-CC) are increasingly being reported in patients with cirrhosis. The aims of this study were (1) to evaluate the incidence, imaging features, and posttransplant outcomes for patients who underwent transplantation for hepatocellular carcinoma (HCC) and were found to have HCC-CC or I-CC in the explant and (2) to compare the outcomes of these patients with those of controls with HCC who were matched (1:3) by the tumor size and the number of nodules in the explant. In the explant specimens of 10 of 302 patients (3.3%) who underwent liver transplantation (LT) for HCC, mixed HCC-CC or I-CC was identified. There were 4 additional incidental cases of HCC-CC. After a median follow-up period of 32 months, 8 of the 14 patients (57%) suffered from tumor recurrence, and the median disease-free survival time was 8 months. The cumulative risk of tumor recurrence was 40% and 70% at 1 and 5 years, respectively, for these 14 patients. When the 4 incidental cases were excluded, the study group with HCC-CC or I-CC (n = 10) had a significantly lower incidence of well-differentiated tumors (11.1% versus 43.3%, P < 0.02) and a higher rate of recurrence (60% versus 16.7%, P = 0.008) in comparison with the control group of patients with HCC (n = 30). The 1- and 5-year cumulative risks of tumor recurrence were 42% and 65%, respectively, in the study group and 10% and 17%, respectively, in the control group (P < 0.002). The actuarial 1- and 5-year patient survival rates without recurrence were also significantly lower in the study group (79% and 32% in the study group and 90% and 62% in the control group, P < 0.03). Dynamic contrast-enhanced computed tomography or magnetic resonance imaging showed progressive contrast enhancement throughout the arterial and portal venous phases without washout in 8 of the 10 patients. In conclusion, HCC-CC and I-CC are associated with a poor prognosis and a high rate of tumor recurrence after LT, and both tumors exhibit radiographic features that are distinct from those observed with HCC. Liver Transpl 17:934–942, 2011. © 2011 AASLD.Keywords
This publication has 24 references indexed in Scilit:
- Pathology of combined hepatocellular‐cholangiocarcinomaJournal of Gastroenterology and Hepatology, 2010
- The Diagnostic Conundrum and Liver Transplantation Outcome for Combined Hepatocellular‐CholangiocarcinomaAmerican Journal of Transplantation, 2010
- Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United StatesLiver Transplantation, 2009
- Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinomaHepatology, 2009
- Liver and Intestine Transplantation in the United States, 1997–2006American Journal of Transplantation, 2008
- Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative ImagingAmerican Journal of Transplantation, 2007
- Predictors of Disease Recurrence Following Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Perihilar CholangiocarcinomaTransplantation, 2006
- Comparison of Combined Hepatocellular and Cholangiocarcinoma with Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaSurgery Today, 2006
- Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canadian experienceLiver Transplantation, 2005
- Combined Hepatocellular and Cholangiocarcinoma: Correlation Between CT Findings and Clinicopathological FeaturesJournal of Computer Assisted Tomography, 1997